Expert Review on the Multidisciplinary Management of Bladder Cancer - Episode 8
For High-Definition, Click
A genome sequencing study examined patients who received everolimus for muscle-invasive bladder. In this study, one patient who was positive for both the lytic protein, Tse1, and neurofibromin 2 (NF2) mutations was particularly sensitive to everolimus therapy, Dean F. Bajorin, MD, notes. Upon further review, it was found that other patients who had received some benefit all had the Tse1 mutation.
Other potentially actionable mutations under investigation include human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3), says Bajorin. Evan Y. Yu, MD, notes that several vascular endothelial growth factor (VEGF) inhibitors, including bevacizumab, ramucirumab, and docetaxel, are being evaluated as second- and third-line treatments of bladder cancer.